Want to see HK:2575 full AI Analyst Report?
Top Page
Xuanzhu Biopharmaceutical Co., Ltd. Class H
(2575)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$13.00
▼(-61.26% Downside)
Action:N/A
Date:07/01/26
The score is mainly held back by persistent operating losses and ongoing negative cash flow, despite clear revenue growth and improving margins. Technically, the stock is in a pronounced downtrend (below major moving averages) with high volatility risk, and valuation support is limited because earnings remain negative and no dividend yield is provided.
Positive Factors
Revenue growth
Sustained strong top-line expansion across 2024–2025 signals meaningful commercial traction and expanding market adoption of the company’s products. Durable revenue scaling improves the odds of achieving operating leverage and supports reinvestment in R&D and commercialization over the medium term.
Negative Factors
Persistent operating and net losses
Repeated operating and net losses show the business has not yet converted revenue growth into profit. Persistent losses erode shareholder value, limit internal funding capacity for expansion, and mean the company must prove durable profitability to justify continued investment and scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
Sustained strong top-line expansion across 2024–2025 signals meaningful commercial traction and expanding market adoption of the company’s products. Durable revenue scaling improves the odds of achieving operating leverage and supports reinvestment in R&D and commercialization over the medium term.
Read all positive factors
Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.90B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)3.73
Revenue Growth72.58%
EPS Growth55.84%
CountryHK
Employees197
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding160,702,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Xuanzhu Biopharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include...
Xuanzhu Biopharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.74M | 56.15M | 32.63M | 32.04K | 0.00 |
| Gross Profit | -5.08M | 21.80M | -12.60M | -35.52M | -30.16M |
| EBITDA | -63.00M | -220.55M | -566.36M | -295.28M | -563.77M |
| Net Income | -69.99M | -266.26M | -603.29M | -332.12M | -595.70M |
Balance Sheet | |||||
| Total Assets | 1.21B | 1.83B | 1.27B | 1.45B | 1.63B |
| Cash, Cash Equivalents and Short-Term Investments | 216.62M | 765.43M | 294.13M | 495.15M | 792.98M |
| Total Debt | 1.37M | 720.64K | 1.57M | 18.79M | 32.82M |
| Total Liabilities | 257.79M | 300.83M | 255.31M | 232.05M | 130.75M |
| Stockholders Equity | 956.22M | 1.53B | 1.02B | 1.22B | 1.50B |
Cash Flow | |||||
| Free Cash Flow | -70.02M | -223.60M | -105.22M | -130.05M | -501.15M |
| Operating Cash Flow | -70.01M | -222.97M | -104.67M | -128.13M | -449.15M |
| Investing Cash Flow | -49.88M | 121.20M | 143.04M | 49.43M | -579.14M |
| Financing Cash Flow | -1.69M | 675.14M | -13.47M | -10.94M | -14.14M |
Xuanzhu Biopharmaceutical Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$179.62B | 27.60 | 16.71% | 0.97% | 22.62% | 26.23% | |
63 Neutral | HK$14.26B | 35.76 | 3.12% | 5.23% | 3.74% | -40.22% | |
55 Neutral | HK$14.64B | 3.95 | 37.04% | ― | -13.04% | 1113.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$6.90B | -26.14 | -53.85% | ― | 72.58% | 55.84% | |
46 Neutral | HK$2.06B | 1.63 | 206.86% | ― | 92.87% | ― | |
44 Neutral | HK$9.96B | 1,780.87 | -0.02% | ― | 31.39% | 98.96% |
* Healthcare Sector Average
HK:2575
Xuanzhu Biopharmaceutical Co., Ltd. Class H
13.33
-15.67
-54.03%
HK:0013
HUTCHMED (China)
16.78
-8.12
-32.61%
HK:2552
Hua Medicine
2.12
-0.98
-31.61%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.03
-1.11
-21.58%
HK:3692
Hansoh Pharmaceutical Group Company Limited
29.62
-0.30
-1.00%
HK:6185
CanSino Biologics, Inc. Class H
22.28
-12.52
-35.98%
Xuanzhu Biopharmaceutical Co., Ltd. Class H Corporate Events
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
Jun 30, 2026
Xuanzhu Biopharmaceutical has reported that China’s National Medical Products Administration has formally accepted its New Drug Application for a new indication of Anaprazole Sodium Enteric-coated Tablets in the treatment of adult reflux eso...
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
Jun 21, 2026
Xuanzhu Biopharmaceutical has enrolled the first patient in a Phase III, multi-centre, randomized, double-blind clinical trial evaluating its innovative proton pump inhibitor Anaprazole Sodium as part of a bismuth-containing quadruple therapy for ...
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
Jun 18, 2026
Xuanzhu Biopharmaceutical Co., Ltd. reported that all resolutions at its 2025 annual general meeting in Beijing were approved by shareholders via poll, including the 2025 board report, audited financial statements, annual report, profit distributi...
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
Jun 18, 2026
Xuanzhu Biopharmaceutical has reshaped its board composition by appointing an employee representative director to replace an executive director position, a move approved at its June 18, 2026 annual general meeting. The change takes effect immediat...
Xuanzhu Biopharmaceutical updates board and committee roles
Jun 18, 2026
Xuanzhu Biopharmaceutical has published an updated list of its board of directors, detailing the roles of executive, non-executive, independent and employee representative members, including Chairperson and General Manager Xu Yanjun. The company a...
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
May 27, 2026
Xuanzhu Biopharmaceutical Co., Ltd., a Hong Kong–listed PRC-incorporated biopharmaceutical company (stock code 2575), has announced the convening of its 2025 annual general meeting in Beijing on June 18, 2026. The meeting will review standar...
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
May 26, 2026
Xuanzhu Biopharmaceutical plans to amend its Articles of Association to streamline governance and modernise its corporate framework, including abolishing its Supervisory Committee and replacing it with an audit committee. The changes also align th...
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
May 12, 2026
Xuanzhu Biopharmaceutical has completed the full circulation of its H shares by converting 357,245,794 previously unlisted shares into H shares, all of which will trade on the Hong Kong Stock Exchange from May 13, 2026. Following the conversion, t...
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
Apr 20, 2026
Xuanzhu Biopharmaceutical announced preliminary Phase 1b data for NG-350A in mismatch repair-proficient locally advanced rectal cancer, presented at the 2026 Annual Meeting of the American Association for Cancer Research. In the ongoing FORTRESS s...
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
Apr 19, 2026
Xuanzhu Biopharmaceutical has reported new Phase III data for its next-generation ALK inhibitor dirozalkib in first-line treatment of ALK-positive advanced non-small cell lung cancer. The multicenter, randomized DIAMOND-2 study in China compared d...
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
Apr 17, 2026
Xuanzhu Biopharmaceutical has obtained approval from the Stock Exchange of Hong Kong to list and allow dealing in 357,245,794 H shares converted from previously unlisted shares under its proposed H share full circulation plan. The move advances th...
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
Apr 14, 2026
Xuanzhu Biopharmaceutical has received approval from China’s drug regulator to launch a Phase III trial of a bismuth-containing quadruple therapy using its Anaprazole Sodium Enteric-coated Tablets for eradicating Helicobacter pylori. The ran...
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
Apr 12, 2026
Xuanzhu Biopharmaceutical has received a notification from the China Securities Regulatory Commission approving the filing for its H share full circulation plan. The approval covers the conversion of 357,245,794 unlisted shares held by six shareho...
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
Apr 9, 2026
Xuanzhu Biopharmaceutical has signed a licensing and supply agreement with Boston Oncology CGT Holding to develop, register and commercialize Bireociclib and Dirozalkib across 21 countries and regions in the Middle East and North Africa. Under the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.